The first large-scale assessment of pharmaceuticals in drinking water in the Czech Republic (CR) focused on the detection of five substances. Samples were collected from public water systems supplying 5.3 million people, 50.5% of the Czech population. In the initial survey of tap water from 92 major supply zones using mostly surface water, no pharmaceutical exceeded the limit of Pharmaceuticals were quantified in only three tap water samples. Regarding risks to consumers, these results suggest that a relatively small population (<10%) in the CR is exposed to quantifiable concentrations of pharmaceuticals in tap water and that an extremely high margin of safety (several thousand-fold to several million-fold) is associated with these exposures.
INTRODUCTION
The occurrence of pharmaceuticals in the environment and water cycle, especially in municipal wastewater and its treated effluent and receiving surface waters, has been reported in a number of studies and summary monographs (e.g. Table 1 . We presume that groundwater sources are only under minimum influence of wastewater, because of their nature and their management.
All water sources supplying more than 10,000 m 3 per year have obligatory protection zones with a special management regime to protect water quality; also many smaller sources have protection zones designated in the CR. Although all surface water treatment plants (WTPs) use coagulation, sand filtration and chlorination, not all of them use advanced initial separation process (e.g. flotation), ozonation or granulated activated carbon. Because these water treatment processes may help reduce the concentrations of some pharmaceuticals and some surface water systems include groundwater sources, it is important to consider tap water concentrations when assessing health risks.
Due to the structure and protection of raw water sources for most of the population using public water systems, we hypothesized that exposure could be low; however, we lacked quantitative information about pharmaceuticals in water to estimate the risks.
In order to better inform the public about the possible risks in the CR, we conducted a systematic survey. The purpose of the study was (1) to detect the occurrence and concentrations of selected pharmaceuticals in both treated and tap water, especially in high-risk areas, and (2) to estimate human exposure to them and to assess average and maximum population health risks relating to such exposures.
METHODS

Selection of pharmaceuticals to be included in survey
Five pharmaceuticals were selected for the survey:
naproxen, ibuprofen, diclofenac, carbamazepine, and 17α-ethinylestradiol. Their characteristics are given in Table 2 .
The selection and number of the pharmaceuticals was based on three factors:
(a) List of substances that are most commonly detected in drinking water above detection levels in other countries (data from available studies) (KNAPPE project ;
Snyder et al. ). No antibiotic was included because of the low detection rates reported to date in drinking water surveys from other countries (KNAPPE project ). On the other hand, despite its low detection rate in drinking water, we included 17α-ethinylestradiol because this hormonally active agent has been intensively discussed both by the mass media and the general public.
Selection of drinking water sampling sites
Drinking water samples were collected during three time periods. The objective of the first survey was a basic screening of tap water from all 14 administrative regions of the CR.
Regional public health authorities were asked to suggest eight of the largest water supply zones based on the number of people supplied, five of them preferably supplying surface water or mixture of ground and surface water and three of them supplying ground water (if possible). Because surface water has a higher probability of wastewater dis- million people. Altogether 15 samples were collected to assess both the WTP outlet and tap water concentrations from the same supply system. We were not allowed to take repeated samples at one WTP, but two samples were collected at the riverbank filtration site using two alternating wells (both wells were sampled). Only seven tap samples from six supply systems are presented, because the samples from two systems were damaged during their processing.
Relationships between sites and samples of survey 2 and 3 as well as short characteristics of the raw water sources are shown in Table 4 . To detect the selected pharmaceuticals, the gas chromatography-mass spectrometry (GC/MS) method was used as previously described by Yu et al. () . In the analysis of survey 1 samples, the protocol of Yu et al. was followed.
However, with the increasing number of analyses performed, the peak response and repeatability became worse and it was necessary to more frequently clean the ion source, liner and whole inlet, particularly due to the use of the derivatization agent injected directly into the GC/MS system. That is why, before analyzing survey 2 and 3 samples, minor modifications were made, primarily in the amount of the derivatization agent used (Kim et al. ;
Kim & Yoon ).
Samples were acidified with concentrated HCl to pH 2-3 and were added with a mixture of surrogates (dihydrocarbamazepine and meclofenamic acid) to a final concentration of 100 ng/L of water. The analytes were used a chromatograph HP 5890 interfaced with an MD 5791 mass selective detector, we did our analysis on a chromatograph Agilent 6890 with a mass selective detector MD 5973, which is thought to be much more sensitive. We used the LOQ rather than the limit of detection to present the results because this proves to be a more accurate estimate of exposure for use in the risk assessment.
Health risk assessment
There is no generally accepted approach to health risk assessment of environmental exposure to drug residues but various approaches have been proposed. 
RESULTS
Detection of pharmaceuticals in drinking water
All of the 92 tap water samples collected in survey 1 were below the LOQ, i.e. <0.5 ng/L for naproxen, ibuprofen, diclofenac, carbamazepine, and 17α-ethinylestradiol.
In survey 2, which focused on potentially high-risk areas and samples at the WTP rather than the tap, all samples from four of 23 WTPs were below the LOQ. In the remaining 19
WTPs, one to three substances were detected above the LOQ: two substances were detected simultaneously in six WTPs (co-occurrence were ibuprofen-carbamazepine, diclo- Table 3 .
In survey 3, concentrations at all WTP outlets were lower than survey 2 samples from corresponding sites;
only three tap water samples from two supply zones were positive for any of the pharmaceuticals monitored, but at relatively low concentrations. Ibuprofen was detected in three tap samples (0.5-1.2 ng/L) and carbamazepine (4.0 ng/L) was present in a single tap sample (co-occurrence ibuprofen-carbamazepine). Interestingly, both of these supply zones were included in survey 1, where all tap water samples were less than the LOQ. All individual results from survey 3 together with results from the same WTPs in survey 2 are presented in Table 4 .
In all samples, the concentration of 17α-ethinylestradiol was below the LOQ, i.e. 0.5 ng/L in survey 1 and 2 ng/L in surveys 2 and 3.
Health risk from drinking water exposure
For all substances except 17α-ethinylestradiol, the MOEs ranged from 10 6 to 10 7 when the exposure estimate considered the maximum concentration in drinking water and all variables were derived from the worst-case deterministic modeling. When median concentrations found in drinking water were considered, the MOEs for the four pharmaceuticals ranged from 10 7 to 10 8 . The data for both exposure scenarios are summarized in Table 5 . Because the health risk expressed as the MOE was computed only for the positive water samples, the above-mentioned individual exposures 18.5 0.6 <2.0 <0.5 <0.5 13.6 <0.5 <2.0 0.5 <0.5 < 0.5 <0.5 <2.0
Limit of quantification: 0.5 ng/L for IBU, NAP, CARB, and DICL; 2 ng/L for EE2. WTPs of supplies 2, 5, and 6 abstract raw water from reservoirs situated in mid or lower reaches of the rivers. WTPs of supplies 1 and 3 abstract raw water from reservoirs situated in upper to mid reaches of the rivers, but have lower water quality. WTPs of supplies 7 and 8 abstract raw water from riverbank filtration situated in the lower reach of the river. WTP 8 uses two alternating wells without mixing and both options were sampled (8a, 8b). WTPs 1, 3, 4, 5 and 6 supply water into 10 water supply zones sampled in survey 1, but in at least three zones water is mixed with another source. The expression 'therapeutic' dose is somewhat misleading, since this pharmaceutical is used on a preventive basis for contraception.
c Since EE2 was always under the limit of quantification, the limit of quantification was used as the theoretical maximum possible concentration for the calculation of MOE and half the limit of quantification was used as the median.
with a positive sample, and in these areas there are about 260,000 people exposed. We assess that not more than 100,000 commuters or an additional 1% is the maximum population that may be partially exposed to the abovementioned levels of pharmaceuticals in drinking water.
For 17α-ethinylestradiol, a hormone that has an extremely low 'therapeutic' dose, the MOE was much lower in the order of 10 3 (3,750 for maximum exposure and 7,500
for median exposure). Because 17α-ethinylestradiol was not detected in a concentration above the LOQ, the higher LOQ (2 ng/L) was used as the theoretical maximum possible concentration in drinking water and one-half of this value was used as the median concentration for computing the MOE. An MOE of 3,750 suggests there is a large difference between the tolerable dose and drinking water exposure, i.e. the assumed safe dose of the hormone is more than 3,750 times greater than the hypothetical maximum daily exposure from drinking water.
DISCUSSION Pharmaceuticals in drinking water
The results of the large-scale sampling of tap water from the major water supply systems in the CR supported our initial hypothesis about the likely low levels of pharmaceuticals in drinking water. The concentrations of the five pharmaceuticals were less than the LOQ in all of the tap water samples of survey 1, even though most samples were collected from systems using, in part or in whole, surface water sources. The most likely explanation is that most surface water sources are protected water supply reservoirs located at the upper reaches of the rivers. That is why we consider exposure relating to our positive findings in 19 WTPs as relevant for less than 10% of the population of the CR. We can confidently say that more than 50% of the population receives drinking water with pharmaceuticals that are below the LOQ (if any).
Health risk
For our health risk assessment, we calculated the MOE for each pharmaceutical by dividing the MTD by the theoretical maximum or median intake from drinking-water. Theoretical maximum and median intake or daily exposure was calculated for each pharmaceutical from maximum and median concentrations found, and an assumed daily water consumption of 2 L. This method was also used by the Drinking Water Inspectorate for England and Wales (DWI), which commissioned a comprehensive desk-based review of current knowledge on and estimation of potential levels of 396 pharmaceuticals and 11 illegal drugs in drinking water in the United Kingdom (DWI ). For the DWI evaluation, an uncertainty factor of 1,000 was applied as a precautionary value. MOEs greater than 1,000 were considered to provide a substantial margin of safety against potential adverse health impacts from exposure to trace concentrations of pharmaceuticals in drinking water.
All MOEs in our evaluation were greater than 1,000: This suggests that the safe dose for chloroform is only five to 15 times greater than the routine exposures from chlorinated drinking water. The MOE for any of the five pharmaceuticals is much larger and suggests that the safe dose is at least 1,000 times greater than the infrequent exposure from only a few water systems. However, based on the high levels of safety observed in our risk assessment for individual substances, we suspect that this may not be a significant factor in interpreting our risk assessment.
There is still no universally accepted method for health risk assessment for environmental exposure to traces of pharmaceuticals, although several approaches have been proposed. Nevertheless, no matter which approach is used, our results indicate very little or no risk to the consumer from the five pharmaceuticals at the concentrations detected in this study (WHO a).
CONCLUSIONS
Our study was motivated by the misleading information disseminated by some mass media on the presence of pharmaceuticals in drinking water in the CR. Because the media reports raised public concern about the accidental and undesirable 'medication' associated with pharmaceuticals in drinking water, we conducted a systematic survey and health risk assessment of selected representative pharmaceuticals to estimate average and maximum population risk.
The results of this survey confirmed our assumption that the occurrence of pharmaceuticals in drinking water in the CR is rare or very low. Our assumption was based on the nature and sources of public drinking water supplies in the CR where almost half of the population receives drinking water obtained from ground water that receives no or very little wastewater discharges. As for the remaining population that receives drinking water from surface sources, the majority (more than 80%) of this population drinks surface water from protected water supply reservoirs These results serve to better inform consumers about the rare occurrence and the low concentrations of pharmaceuticals found in public water systems in the CR. Outputs of our study included the following:
• A brief press release and a more detailed web report for the general public explaining the issue and its health and environmental importance.
• A public announcement through media and website about the consumer's role in helping to maintain high quality water, e.g. responsible drug use, especially disposal of unwanted drugs (by law, all pharmacies in the CR must take back expired, unwanted, or unused drugs, and consumers should return these pharmaceutics for incineration rather than placing them in the garbage or flushing them into the sewers).
• Detailed information for water producers, in particular for those operating in high-risk areas, on how to approach this issue (monitoring of selected pharmaceuticals in risky supplies, treatment options) and on how to openly and truthfully communicate it with consumers (publishing of occurrence if found, levels and relevant health risk using relative exposure approach, recommendation as to what can be done by consumers to decrease environmental load by pharmaceuticals) in a similar way to the information brochure issued by the American Water Work Association (Hoffbuhr ).
